The Effect of Age Correction on Multivariate Classification in Alzheimer’s Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects
Year: 2015
Type: article
Study design: Observational Study
Abstract: The similarity of atrophy patterns in Alzheimer's disease (AD) and in normal aging suggests age as a confounding factor in multivariate models that use structural magnetic resonance imaging (MRI) data. To study the effect and compare different age correction approaches on AD diagnosis and prediction of mild cognitive impairment (MCI) progression as well as investigate the characteristics of correctly and incorrectly classified subjects. Data from two multi-center cohorts were included in the study [AD = 297, MCI = 445, controls (CTL) = 340]. 34 cortical thickness and 21 subcortical volumetric measures were extracted from MRI. The age correction approaches involved: using age as a covariate to MRI-derived measures and linear detrending of age-related changes based on CTL measures. Orthogonal projections to latent structures was used to discriminate between AD and CTL subjects, and to predict MCI progression to AD, up to 36-months follow-up. Both age correction approaches improved models' quality in terms of goodness of fit and goodness of prediction, as well as classification and prediction accuracies. The observed age associations in classification and prediction results were effectively eliminated after age correction. A detailed analysis of correctly and incorrectly classified subjects highlighted age associations in other factors: ApoE genotype, global cognitive impairment and gender. The two methods for age correction gave similar results and show that age can partially masks the influence of other aspects such as cognitive impairment, ApoE-e4 genotype and gender. Age-related brain atrophy may have a more important association with these factors than previously believed.
Source: Brain Topography
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,390
Funders: U.S. Department of Defense, Foundation for the National Institutes of Health, Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Roche, Biogen, University of Southern California, Medpace, Meso Scale Diagnostics, Synarc, Alzheimer's Disease Neuroimaging Initiative, BioClinica, Itä-Suomen Yliopisto, Novartis Pharmaceuticals Corporation, Northern California Institute for Research and Education, Loo och Hans Ostermans Stiftelse för Medicinsk Forskning, National Institute for Health and Care Research, European Commission, Fondation pour la Recherche Médicale, Eisai, Karolinska Institutet, Kuopion Yliopistollinen Sairaala, Stockholms Läns Landsting, Swedish Brain Power, Servier, IXICO, National Institutes of Health, Genentech, University of California, San Diego, National Institute on Aging, National Institute of Biomedical Imaging and Bioengineering
Awards: G1012222616, NIHR Senior Investigator Award, G2423387114, G2522063444, G2835601961, G29951154, G3146424788, G3420704675, G3870774570, G3966393351, G4119534169, G4196769506, G4401988282, G4475667458, G4860885537, G5324093878, EFFECTS OF TRAUMATIC BRAIN INJURY (TBI) AND POST TRAUMATIC STRESS DISORDER (PTSD) ON ALZHEIMER'S DISEASE (AD) IN VETERANS USING IMAGING AND BIOMARKERS IN THE AD NEUROIMAGING INITIATIVE (ADNI)", Alzheimer's Disease Neuroimaging Initiative, G7234197675, G9000074849, G9000122335, G920654007
OpenAlex ID: W2255469161
